Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
The Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire, a recommended measure of patient-reported impact for psoriatic arthritis (PsA), was initially developed in Europe and may lack universal validity. Recognizing the need for a culturally appropriate tool for Arab patients, this study aimed to TranslAte, CulTurally adapt, and validate the PsAID in ArabIC (TACTIC). The PsAID-12 was translated into Arabic using a rigorous process of double translation, back-translation, and cognitive debriefing. The Arabic version was then validated through a study conducted in 13 Arab countries in 2022. Participants were consecutive literate adult patients diagnosed with PsA and fulfilling the CASPAR criteria. Collected data included PsAID-12, disease activity, and legacy patient-reported outcomes. Psychometric properties, such as internal consistency, construct validity, and test-retest reliability, were examined. Factors associated with high PsAID-12 total scores (> 4) were explored using multivariable binary logistic regression. A culturally adapted Arabic PsAID-12 questionnaire was achieved with minor rephrasing. The validation study included 554 patients from 13 countries (mean age 45 years, 59% females), with a mean PsAID score of 3.86 (SD 2.33). The Arabic PsAID-12 demonstrated excellent internal consistency (Cronbach's α = 0.95), and correlations with other measures ranged from 0.63 to 0.78. Test-retest reliability (N = 138 patients) was substantial (intraclass correlation coefficient, ICC 0.90 [0.86-0.93]; Cohen's kappa 0.80). Factors associated with a high PsAID score were disability (odds ratio, OR 3.15 [2.03-4.89]), depression (OR 1.56 [1.35-1.81]), widespread pain (OR 1.31 [1.12-1.53]), and disease activity (OR 1.29 [1.13-1.47]). Pain and fatigue were identified as the most impactful PsAID-12 domains for PsA patients. The Arabic PsAID is a valid and reliable measure that reflects the priorities of patients with PsA. PsAID scores correlated with disease activity and legacy outcome measures, as expected, indicating PsAID is a consistent measure of PsA impact across cultures. These findings highlight the potential of the Arabic PsAID in improving the care provided to Arabic-speaking patients worldwide.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Rheumatology international - 44(2024), 5 vom: 28. Apr., Seite 885-899 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ziadé, Nelly [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arab countries |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00296-024-05552-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369878353 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369878353 | ||
| 003 | DE-627 | ||
| 005 | 20240401232829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-024-05552-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM369878353 | ||
| 035 | |a (NLM)38498150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ziadé, Nelly |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a The Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire, a recommended measure of patient-reported impact for psoriatic arthritis (PsA), was initially developed in Europe and may lack universal validity. Recognizing the need for a culturally appropriate tool for Arab patients, this study aimed to TranslAte, CulTurally adapt, and validate the PsAID in ArabIC (TACTIC). The PsAID-12 was translated into Arabic using a rigorous process of double translation, back-translation, and cognitive debriefing. The Arabic version was then validated through a study conducted in 13 Arab countries in 2022. Participants were consecutive literate adult patients diagnosed with PsA and fulfilling the CASPAR criteria. Collected data included PsAID-12, disease activity, and legacy patient-reported outcomes. Psychometric properties, such as internal consistency, construct validity, and test-retest reliability, were examined. Factors associated with high PsAID-12 total scores (> 4) were explored using multivariable binary logistic regression. A culturally adapted Arabic PsAID-12 questionnaire was achieved with minor rephrasing. The validation study included 554 patients from 13 countries (mean age 45 years, 59% females), with a mean PsAID score of 3.86 (SD 2.33). The Arabic PsAID-12 demonstrated excellent internal consistency (Cronbach's α = 0.95), and correlations with other measures ranged from 0.63 to 0.78. Test-retest reliability (N = 138 patients) was substantial (intraclass correlation coefficient, ICC 0.90 [0.86-0.93]; Cohen's kappa 0.80). Factors associated with a high PsAID score were disability (odds ratio, OR 3.15 [2.03-4.89]), depression (OR 1.56 [1.35-1.81]), widespread pain (OR 1.31 [1.12-1.53]), and disease activity (OR 1.29 [1.13-1.47]). Pain and fatigue were identified as the most impactful PsAID-12 domains for PsA patients. The Arabic PsAID is a valid and reliable measure that reflects the priorities of patients with PsA. PsAID scores correlated with disease activity and legacy outcome measures, as expected, indicating PsAID is a consistent measure of PsA impact across cultures. These findings highlight the potential of the Arabic PsAID in improving the care provided to Arabic-speaking patients worldwide | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arab countries | |
| 650 | 4 | |a Arabic | |
| 650 | 4 | |a Patient-reported outcomes | |
| 650 | 4 | |a PsAID | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 4 | |a Questionnaire validation | |
| 700 | 1 | |a Abbas, Noura |e verfasserin |4 aut | |
| 700 | 1 | |a Hmamouchi, Ihsane |e verfasserin |4 aut | |
| 700 | 1 | |a El Kibbi, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Maroof, Avin |e verfasserin |4 aut | |
| 700 | 1 | |a Elzorkany, Bassel |e verfasserin |4 aut | |
| 700 | 1 | |a Abdulateef, Nizar |e verfasserin |4 aut | |
| 700 | 1 | |a Adnan, Asal |e verfasserin |4 aut | |
| 700 | 1 | |a Ihsan Awadh, Nabaa |e verfasserin |4 aut | |
| 700 | 1 | |a Gorial, Faiq Isho |e verfasserin |4 aut | |
| 700 | 1 | |a Alchama, Nada |e verfasserin |4 aut | |
| 700 | 1 | |a Haouichat, Chafika |e verfasserin |4 aut | |
| 700 | 1 | |a Alnaimat, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Hannawi, Suad |e verfasserin |4 aut | |
| 700 | 1 | |a Atawnah, Saed |e verfasserin |4 aut | |
| 700 | 1 | |a Halabi, Hussein |e verfasserin |4 aut | |
| 700 | 1 | |a Al Mashaleh, Manal |e verfasserin |4 aut | |
| 700 | 1 | |a Aljazwi, Laila |e verfasserin |4 aut | |
| 700 | 1 | |a Abogamal, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Ayoub, Laila |e verfasserin |4 aut | |
| 700 | 1 | |a Bouajina, Elyes |e verfasserin |4 aut | |
| 700 | 1 | |a Bahiri, Rachid |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Sabkar, Maha |e verfasserin |4 aut | |
| 700 | 1 | |a Aouad, Krystel |e verfasserin |4 aut | |
| 700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d 1985 |g 44(2024), 5 vom: 28. Apr., Seite 885-899 |w (DE-627)NLM012644315 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:5 |g day:28 |g month:04 |g pages:885-899 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00296-024-05552-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 5 |b 28 |c 04 |h 885-899 | ||